VIR 8190
Alternative Names: VIR-8190Latest Information Update: 24 May 2024
At a glance
- Originator GSK; Vir Biotechnology
- Developer Vir Biotechnology
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Metapneumovirus infections; Respiratory syncytial virus infections
Most Recent Events
- 03 May 2024 Vir Biotechnology plans to file IND for Respiratory syncytial virus infections and Metapneumovirus infections within next 18 months
- 08 Aug 2023 Preclinical trials in Metapneumovirus infections (Prevention) in USA (Parenteral) before August 2023
- 08 Aug 2023 Preclinical trials in Respiratory syncytial virus infections (Prevention) in USA (Parenteral) before August 2023